Hereditary medullary thyroid carcinoma: How molecular genetics made multiple endocrine neoplasia type 2 a paediatric disease

Endocrine Development

Volumn 10, Issue , 2007, Pages 173-187

  Szinnai, G ^a,c   Sarnacki, S ^b   Polak, M ^a  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; RET PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CHILD; CLASSIFICATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; HUMAN; MEDULLARY CARCINOMA; MOLECULAR BIOLOGY; MUTATION; PATHOLOGY; REVIEW; SIPPLE SYNDROME; THYROID TUMOR; THYROIDECTOMY;

CARCINOMA, MEDULLARY; CHILD; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HETEROZYGOTE; HUMANS; MOLECULAR BIOLOGY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 35148875278     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000106826     Document Type: Review

References (36)

1. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder B: Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
2. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TG, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
3. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C: Genotype-phenotype correlation in multiple endocrine neoplasia type2: report of the International RET Mutation Consortium. J Intern Med 1995;238:343-346.
4. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-1579.
5. Szinnai G, Meier C, Komminoth P, Zumsteg UW: Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003;111:E132-E139.
6. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roehrer HD, Wahl RA, Lamesch P, Raue F, Conte-Delvolx B, Dralle H; European Multiple Endocrine Neoplasia (EUROMEN) Study Group: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
7. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Delvolx B, Falchetti A, Gheri RG, Libraia A, Lips CJM, Lombardi G, Mannelli M, Pacini F, Ponder BAJ, Raue F, Skogseid B, Tamburano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ: Guidelines for diagnosis and therapy of MEN type 1 and 2. J Clin Endocrinol Metab 2001;86:5658-5671.
8. Ponder BA: Multiple endocrine neoplasia type 2; in Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer. New York, McGraw-Hill, 2002, pp 501-513.
9. Ponder BAJ, Ponder MA, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple P, Easton DP: Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988;i:397-401.
10. National Cancer Institute: Genetics of medullary thyroid cancer. http://www.cancer.gov/cancertopics/pdq/genetics/medullarythyroid/ HealthProfessional/page2.
11. Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH Jr: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 1980;115:142-148.
12. Wolfe HJ, Melvin KE, Cervin-Skinner SJ, Saadi AA, Juliar JF, Jackson CE, Tashjian AH Jr: C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-441.
13. Niccoli P, Wion-Barbot N, Carron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Delvolx B: Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997;82:338-341.
14. Gagel RF, Tashjian AH Jr, Cummings T, Papathanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A: an 18-year experience. N Engl J Med 1988;318:478-484.
15. Skinner MA, Moley JA, Dilley WG, Owzar K, DeBenedetti MK, Wells SA Jr: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
16. Leboulleux S, Travagli JP, Caillou B, Laplanche A, Bidart JM, Schlumberger M, Baudin E: Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome. Cancer 2002;94:44-50.
17. Modiglioni E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, Rosenberg-Bougin M, Calmettes C, et al: Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The EUROMEN Study Group. J Intern Med 1995;238:363-367.
18. Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E: Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs à Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 1996;20:808-812.
19. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A: Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448-5451.
20. Marx SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367-375.
21. Ito S, Iwashita T, Asai N, Muratami H, Iwata Y, Sobue G, Takahashi M: Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 1997;57:2870-2872.
22. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Vecchio G, Fusco A, Kraus M, Di Fiore PP: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-383.
23. American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
24. Lips CJM, Landsvater RM, Höppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils APG, De Wit M, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, van Vroonhoven TJMV, Vroom TM: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-835.
25. Schuffenecker I, Ginet N, Godgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM: Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs à Calcitonin. Am J Hum Genet 1997;60:233-237.
26. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ: Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994;55:1076-1082.
27. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB: Multiple endocrine neoplasia type 2: evaluation of genotype-phenotype relationship. Arch Surg 2003;138:409-416.
28. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M: Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996;129:459-464.
29. Frohnauer MK, Decker RA: Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000;128:1052-1058.
30. Gimm O, Ukkat J, Niederle BE, Weber T, Tanh PN, Brauckhoff M, Niederle B, Dralle H: Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related mutations not affecting codon 634. World J Surg 2004;28:1312-1316.
31. Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J, Ponder BAJ: Germline homozygous mutations at codon 804 in the RET proto-oncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 2005;90:3454-3457.
32. Quayle FJ, Moley JF: Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes. J Surg Oncol 2005;89:122-129.
33. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H: Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005;257:50-59.
34. Inabnet W, Caragliano P, Pertsemlidis D: Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 2000;128:1007-1012.
35. Strock CJ, Park JI, Rosen M, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD: Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006;91:79-84.
36. de Groot JWB, Links TP, Plukker JTM, Lips CJM, Hofstra RMW: RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-560.